+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease



No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease



Gastroenterology 152(4): 787-798.E2



Gluten ingestion leads to symptoms and small intestinal mucosal injury in patients with celiac disease. The only option is the strict lifelong exclusion of dietary gluten, which is difficult to accomplish. Many patients following a gluten-free diet continue to have symptoms and have small intestinal mucosal injury. Nondietary therapies are needed. We performed a phase 2 study of the ability of latiglutenase, an orally administered mixture of 2 recombinant gluten-targeting proteases, to reduce mucosal morphometric measures in biopsy specimens from patients with celiac disease. We performed a double-blind, placebo-controlled, dose-ranging study to assess the efficacy and safety of latiglutenase in 494 patients with celiac disease (with moderate or severe symptoms) in North America and Europe, from August 2013 until December 2014. Participants reported following a gluten-free diet for at least 1 year before the study began. Patients with documented moderate or severe symptoms and villous atrophy (villous height:crypt depth ratio of ≤2.0) were assigned randomly to groups given placebo or 100, 300, 450, 600, or 900 mg latiglutenase daily for 12 or 24 weeks. Subjects completed the Celiac Disease Symptom Diary each day for 28 days and underwent an upper gastrointestinal endoscopy with duodenal biopsy of the distal duodenum at baseline and at weeks 12 and 24. The primary end point was a change in the villous height:crypt depth ratio. Secondary end points included numbers of intraepithelial lymphocytes, serology test results (for levels of antibodies against tissue transglutaminase-2 and deamidated gliadin peptide), symptom frequencies, and safety. In a modified intent-to-treat population, there were no differences between latiglutenase and placebo groups in change from baseline in villous height:crypt depth ratio, numbers of intraepithelial lymphocytes, or serologic markers of celiac disease. All groups had significant improvements in histologic and symptom scores. In a phase 2 study of patients with symptomatic celiac disease and histologic evidence of significant duodenal mucosal injury, latiglutenase did not improve histologic and symptom scores when compared with placebo. There were no significant differences in change from baseline between groups. ClinicalTrials.gov no: NCT01917630.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058410700

Download citation: RISBibTeXText

PMID: 27864127

DOI: 10.1053/j.gastro.2016.11.004


Related references

Endoscopic markers of villous atrophy are not useful for the detection of celiac disease in patients with dyspeptic symptoms. Endoscopy 38(7): 696-701, 2006

Mo1044 - Correlation of Histologic, Serologic, and Symptomatic Measures of Celiac Disease Patients Participating in a Latiglutenase Clinical Trial. Gastroenterology 154(6): S-682, 2018

Latiglutenase Improves Symptoms in Seropositive Celiac Disease Patients While on a Gluten-Free Diet. Digestive Diseases and Sciences 62(9): 2428-2432, 2017

Nutritional status of newly diagnosed celiac disease patients before and after the institution of a celiac disease diet--association with the grade of mucosal villous atrophy. American Journal of Clinical Nutrition 67(3): 482-487, 1998

Screening for celiac disease in Down's syndrome patients revealed cases of subtotal villous atrophy without typical for celiac disease HLA-DQ and tissue transglutaminase antibodies. World Journal of Gastroenterology 12(9): 1430-1434, 2006

Patients of celiac disease with mild villous atrophy are clinically similar to those with moderate to severe atrophy. Indian Journal of Gastroenterology 32(6): 413-414, 2014

M2054 Correlation of Histological Villous Atrophy with Tissue Transglutaminase Antibody Level in Patients with Diagnosis of Celiac Disease: Retrospective Analysis of a Cohort of 187 Celiac Patients. Gastroenterology 136(5): A-475-A-476, 2009

Sa1315 Vitamin D Deficiency Does Not Correlate With Villous Atrophy in Patients With Celiac Disease. Gastroenterology 142(5): S-271, 2012

Classification of villous atrophy with enhanced magnification endoscopy in patients with celiac disease and tropical sprue. Gastrointestinal Endoscopy 66(2): 377-382, 2007

Recommendations to quantify villous atrophy in video capsule endoscopy images of celiac disease patients. World Journal of Gastrointestinal Endoscopy 8(18): 653-662, 2016

Sa1294 Lymphocytic Gastritis in Patients With Celiac Disease; Increasing Prevalence According to Age and Severity of Villous Atrophy. Gastroenterology 148(4): S-284, 2015

Extraction and processing of videocapsule data to detect and measure the presence of villous atrophy in celiac disease patients. Computers in Biology and Medicine 78: 97-106, 2016

Optical coherence tomography in pediatric patients: a feasible technique for diagnosing celiac disease in children with villous atrophy. Digestive and Liver Disease 41(9): 639-643, 2009

Total villous atrophy mesenteric lymph node cavitation splenic atrophy a special form of adult celiac disease a new case. Annales De Pathologie: 251-256, 1983

Total villous atrophy, mesenteric lymph-node cavitation, splenic atrophy. An unusual form of celiac disease in adults, apropos of a new case. Annales de Pathologie 3(3): 251-256, 1983